Successful Phase II trial for ponesimod (Actelion) in Plaque Psoriasis

Actelion has announced that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study conducted in 326 patients with moderate to severe chronic Plaque Psoriasis. Results of the primary endpoint were highly statistically significant with both tested doses.

With Ponesimod 20 mg, 46 % of patients improved by at least 75 % at week 16 (p<0.0001 versus placebo. with ponesimod 40 mg 48.1 of patients improved by at least 75 at week 16 p><0.0001 versus placebo. an improvement by at least 75 was observed at week 16 in 13.4 of the placebo treated patients. both doses were administered once daily.ponesimod will now proceed to phase iii in its clinical development in psoriasis . http>